Low-doses Alemtuzumab and Rituximab Combination as First Line Treatment in Aplastic Anemia
- Patients with aplastic anemia diagnosis
- Patients with prior treatment with monoclonal antibodies and/or antithymocyte
- Patients with a diagnosis or history of HIV/AIDS, Hepatitis B, Hepatitis C,
- Patients who do not agree to sign a Letter of Informed Consent.
Type of Study:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Evaluate efficacy of alemtuzumab and rituximab in aplastic anemia.
Evaluate the hematological response after the administration of alemtuzumab and rituximab
Outcome Time Frame:
David Gomez Almaguer, MD
Hospital Universitario Dr. Jose E. Gonzalez
Mexico: Ministry of Health
- Aplastic Anemia
- Aplastic anemia
- Anemia, Aplastic